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Abstract
Background: Up to now, the role of adjuvant radiation therapy and the extent of lymph node dissection for early
stage endometrial cancer are controversial. In order to clarify the current position of the given adjuvant treatment
options, a systematic review was performed.
Materials and methods: Both, Pubmed and ISI Web of Knowledge database were searched using the following
keywords and MESH headings: “Endometrial cancer”, “Endometrial Neoplasms”, “Endometrial Neoplasms/
radiotherapy”, “External beam radiation therapy”, “Brachytherapy” and adequate combinations.
Conclusion: Recent data from randomized trials indicate that external beam radiation therapy - particularly in
combination with extended lymph node dissection - or radical lymph node dissection increases toxicity without
any improvement of overall survival rates. Thus, reduced surgical aggressiveness and limitation of radiotherapy to
vaginal-vault-brachytherapy only is sufficient for most cases of early stage endometrial cancer.
Introduction
Over years there has been a constant debate regarding
the extent of the lymph node dissection and the role of
adjuvant treatments for localized endometrial carcinoma.
Especially the role of adjuvant radiation treatment has
not yet been well defined.
An early analysis from the GOG-database documented a
clear correlation between tumour size, tumour grade and
the subsequent risk of local failure, loco-regional failure
and distant seeding [1,2]. Thus complex pattern of parallel
and competing risks exist.
In order to reduce the vaginal vault failures and lymph
node failures brachytherapy alone, percutaneous pelvic
radiation alone or in combination with afterloading proce-
dures has been employed [3-8].
Until now the final impact of these strategies on over-
all survival has only been weakly defined.
In parallel, it has been speculated that local control
may be increased by an extended lymph node dissection
[9-12]. Again, the precise value of increased surgical
aggressiveness has not been validated.
Aim of the article is to critically review the available
data and the recently published randomized trials.
Major trials and randomized radiotherapy trials
At present the data of the following prospective or ran-
domized trials determining the role of radiation as
adjunct to surgical procedures for patients with endo-
metrial carcinoma are available:
Poulsen and co-workers published the oldest trial
regarding the use of radiation therapy in 1997 [13,14].
The Danish group analysed the outcomes in patients
prospectively chosen to receive no external radiation in
pT1 low risk (n = 641) whereas pT1 high risk (n = 235),
stage II (n = 105) and stage III group 1 (n = 58) were
treated regularly.
Tumour recurrences occurred in 7% in stage I low-risk
patients, 15% in stage I high-risk patients, 29% of stage II,
and 47% of stage III patients. The conclusion was to omit
external radiotherapy from treatment concept for
patients with low risk endometrial cancer.
However, a major shortcoming of the trial was the
missing of randomization. Thus several randomized
trials were initiated.
The Gynaecological Oncology Group (GOG-99 trial)
was designed to analyse the value of adjuvant percuta-
neous radiotherapy in patients with stage I and stage II
endometrial carcinoma. The surgical procedure was sta-
ted to have included lymphadenectomy (LAE). However,* Correspondence: claus.belka@med.uni-muenchen.de
Universitiy of Munich - LMU, Department of Radiation Oncology,
Marchioninistrasse 15, 81377 Munich, Germany
Scheithauer et al. Radiation Oncology 2011, 6:164
http://www.ro-journal.com/content/6/1/164
© 2011 Scheithauer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
the extent of LAE (number of node retrieved, lymph
node areas dissected) was not documented.
Although the trial was initially designed as prospective
trial, it became apparent that the targeted patient popu-
lation was at a lower risk for recurrence than initially
expected. Therefore, the initial definition of risk groups
was replaced. Thus, on a formal basis the trial cannot
be considered as pure prospective trial.
Using the ex post risk definition, patients with high-risk
features had an increased rate of recurrences which trans-
lated into a reduced overall survival rate. High risk was
defined as a complex combination of age and other risk
factors (moderately to poorly differentiated tumours,
lymph vessel invasion, outer third invasion). High-risk
phenotype was defined as age > 70 and one other factor,
> 50 with any two of the other risk factors, or any age with
three of the other risks. Patients with these constellations
benefited significantly from pelvic irradiation [7,15].
In parallel, the PORTEC study group also aimed to
determine the impact of pelvic irradiation without addi-
tional brachytherapy on the outcome in patients with
early stage endometrial cancer [8].
In this regard the surgical procedure was a simple
total abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAH-BSO) without any lymphadenect-
omy. Patients were mainly diagnosed with pT1b G2
31%, pT1b G3 10%, pT1c G1 20%, pT1c G2 39%, pT1c
G3 < 1%.
Without randomisation, patients with a pT1c G3 car-
cinoma were treated routinely with pelvic irradiation
and were followed in a register-only arm of the trial
[16].
In principle, pelvic irradiation was found to be impor-
tant for local control (HR 3,9; 2.0-7,6), however, omis-
sion of radiotherapy did not impact on overall survival
(0,76; 0,4-1,4).
When analysing this trial in detail it becomes obvious
that at least one third of the patients had only a very
limited risk for pelvic lymph node involvement. Thus, it
is not surprising that the increase in local control does
not frankly translate into a survival benefit.
Patients with pT1c G3 (n = 99) routinely received pel-
vic irradiation resulting in 5% vaginal relapse and pelvic
relapses in 7%. The fate of these patients was dominated
by a high distant failure rate (31%). Thus, even in
absence of an extended surgical procedure local control
is adequate [16].
Long term follow up of this trial confirmed the initial
interpretation that pelvic radiotherapy is an overtreat-
ment for low to intermediate risk patients [17]. This is
of special importance when bearing in mind that pelvic
irradiation is associated with a mildly but clearly
increased risk of side effects [18]. Taken together,
although the PORTEC-1 trial was designed to answer
the question which cohort would benefit from pelvic
irradiation, it finally failed to really define a clear subset
of patients in need of pelvic irradiation. Several other
questions were not addressed by the trial: Since in paral-
lel with the upcoming of the randomized data, several
cohorts of patients treated with brachytherapy only were
reported, the evident question was in how far local vagi-
nal radiotherapy alone would be suitable [19-21].
Not directly related to the use of radiotherapy both
randomized trials left open the question in how far the
degree of lymphadenectomy would influence the use of
radiotherapy and finally, the question in how far distant
failure would be decreased by adding aggressive poly-
chemotherapy.
The PORTEC-2 and the MRC ASTEC and NCIC
CTG EN.5 trial represent the logical continuation of the
aforementioned research issues. Whereas the PORTEC-
2 trial analysed the role of pelvic irradiation compared
to vaginal vault brachytherapy, the ASTEC/EN.5 group
initiated a complex trial aiming to define the role of
both, adjuvant pelvic radiotherapy and systematic pelvic
lymphadenectomy.
ASTEC/EN.5 radiotherapy trial
For a better understanding of radiotherapy and of lymph
node dissection the NCIC and the MRC designed a dou-
ble randomization based trial setting (referred to as
ASTEC, “A Study in the Treatment of Endometrial Can-
cer” for the MRC part of the trial and “EN.5” for the
NCIC part of the trial) [22,23].
In a first approach, patients with endometrial cancer
were randomized to receive TAH-BSO with or without
lymphadenectomy. In a subsequent step patients with
intermediate or high-risk early cancer were randomly
assigned to pelvic irradiation versus no pelvic irradia-
tion. Vaginal vault brachytherapy was done based on the
individual centre policy. Main endpoint of the trial was
overall survival.
The majority of patients were diagnosed pT1c (24%
G1, 37% G2, 11% G3). The collective included sufficient
numbers of patients harbouring a reasonable risk of
lymph node seeding. Pelvic irradiation significantly
reduced the number of local and loco-regional relapses.
However, in absolute numbers, the level of risk reduc-
tion was low (29/453 versus 13/452).
The major result of the trial showed that overall survival
with external beam radiotherapy was not better than after
observation (hazard ratio 1.05; 95% CI 0.75-1.48; p = 0.77),
both groups had a 5-year overall survival rate of 84%. In
the framework of this trial the authors performed a meta-
analysis of all previous trials confirming that there is no
benefit in terms of overall survival (hazard ratio 1.04; 95%
CI 0.84-1.29). Statistically an absolute benefit of external
beam radiotherapy at 5 years of more than 3% could be
readily excluded.
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However it has to be taken into account that roughly
50% of the patients in the observation arm received
vaginal vault brachytherapy leading to an underestima-
tion of the net effects of irradiation.
Since the rate of distant failures was merely equal in
both arms the small improvements in local control did
not translate into an improvement of overall survival. In
addition, the trial revealed a mildly but clearly visible
increase in early and late toxicity.
Nevertheless, some criticism was issued especially in
regard to patient selection biases [24]:
Creasman and co-workers commented, “Only one
third of the surgical patients from the first study were
actually secondarily randomized to radiation therapy”.
Furthermore “Patients could have lymph node metasta-
sis confirmed on pathology yet be randomized to no
external beam radiation therapy (EBRT)”.
In addition, only less than one third of the patients
had lymph node dissection and of those less than 20%
had an adequate dissection. Thus the majority of the
patients may have been not adequately staged. A further
bias is generated by the fact that brachytherapy was
used in roughly 50% of the patients assigned to the
observation arm. Since brachytherapy is efficiently redu-
cing the local relapse rate putative effects of pelvic irra-
diation may be diluted.
PORTEC-2 radiotherapy trial
The initial PORTEC-1 trial documented that pelvic irra-
diation in the absence of a systematic lymphadenectomy
increased local control in low-intermediated risk patients,
however overall survival was not influenced and toxicity
was increased [17]. Based on these results, the Dutch con-
sortium commenced a new randomized trial addressing
the question in how far whole pelvic irradiation or bra-
chytherapy alone is sufficient for patients with intermedi-
ate risk endometrial carcinoma [25,26].
The study collective (n = 427) comprised patients with
pT1b, pT1c carcinomas grade 1 and grade 2. Surgery was
TAH-BSO without any additional lymph node dissection.
Primary endpoint was vaginal vault failure with overall
survival and quality of life being secondary endpoint. 5-
year rates of vaginal recurrence were calculated as fol-
lowed: Vaginal brachytherapy 1.8% (95% CI 0.6-5.9) vs.
1.6% (95% CI 0.5-4.9) after pelvic radiotherapy (HR EBRT
0.78, 95% CI 0.17-3.49; p = 0.74). The combination of
vaginal and pelvic failures revealed 5-year rates of loco-
regional recurrence of 5.1% (2.8-9.6) after brachytherapy,
and 2.1% (0.8-5.8) for EBRT (HR 2.08, 0.71-6.09; p = 0.17).
Rates of distant metastases were similar in both arms. Key
observation was the fact that no differences in overall or
disease-free survival occurred. However, acute grade 1-2
gastrointestinal toxicity was significantly lower in bra-
chytherapy when compared to the EBRT patients. A
subsequent analysis of health-related quality of life
(HRQOL) issues and side effects confirmed these results
[27].
Similar to the ASTEC/EN.5 trial several issues are still
not solved by this trial. After central pathology review it
turned out that most of the patients suffered from dee-
ply invasive grade 1 cancer. Thus the translation of
these results to the general collective of intermediate
risk patients may not be justified [28].
In her comment P. Eifel concluded that “even with
more than 400 patients, PORTEC-2 was probably statis-
tically underpowered; in part, because of the large pro-
portion of relatively low-risk, grade 1 tumours, the total
number of events was small” [28].
Other major recent analysis
Since all given randomized trials do not completely
answer the open questions in how far pelvic radiother-
apy improves overall survival after endometrial carci-
noma a SEER data base analysis was undertaken: In this
regard, 56.360 eligible patients were identified with
70.4% low, 26.2% intermediate, and 3.4% high risk. A
proportion of 41.6% underwent LAE and 17.6% adjuvant
RT. In low-risk disease, RT was not associated with
increased survival whereas in intermediate-risk disease
lymphadenectomy and RT (80.6% RT vs. 74.9% no RT,
p < 0.001) were associated with higher survival without
differences between RT modalities. In high-risk disease
lymphadenectomy and irradiation were associated with
increased survival. In the absence of lymphadenectomy
pelvic irradiation was superior to brachytherapy only
(p = 0.01)[29].
Role of lymphadenectomy
The value of systematic lymphadenectomy for adequate
staging is well accepted for many cancer sites. In con-
trast, final prove is lacking that an extended lymphade-
nectomy is able to impact on overall survival.
In case of endometrial carcinoma, several non-rando-
mized trials including a SEER data based survey indi-
cated that the number of removed lymph nodes
correlates with an increased overall survival [9,12].
These finding were the rationale for increasing the
aggressiveness of the surgical approach in several coun-
tries. However, any analysis based on SEER data may
harbour a massive bias. In this regard, the SEER analysis
revealed that the number of lymph nodes removed also
correlated to a reduction of the non-tumour related
death rates [12,30]. Thus it seems likely that surgeons
tended to remove more nodes in healthier patients.
In order to avoid the inherent shortcomings from ret-
rospective approaches and SEER data base analysis,
randomized trails had to be performed. In this regard
the results from two major trials have been published
recently [23,30].
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The Italian trial randomized 514 patients with preo-
perative stage I endometrial carcinoma to undergo pelvic
systematic lymphadenectomy (n = 264) or no lymphade-
nectomy (n = 250). The primary endpoint of the trial was
overall survival with disease-free survival and surgical
morbidity being secondary endpoint. No influence on
overall survival was detectable. However, surgical staging
was improved with more positive lymph nodes detected.
In parallel, the toxicity was significantly increased. The
use of radiation and other adjuvant treatments were at
the discretion of the treating physician. In the lymphade-
nectomy arm 44 patients (16.7%) received irradiation
whereas in the observation arm 63 patients (25.2%) were
treated with radiotherapy.
In a similar approach, the ASTEC/EN.5 trial rando-
mized 1408 women with histologically proven endome-
trial carcinoma confined to the corpus to surgery
(hysterectomy and BSO; n = 704) or surgery plus lym-
phadenectomy (n = 704). Again, the primary endpoint
of the trial was overall survival. The reported absolute
difference in 5-year overall survival was 1% (95% CI -4
to 6). After adjustment for baseline characteristics and
pathology details, no significant differences in either
overall survival or recurrence free survival were detect-
able. Data on acute or late toxicity were not reported.
The issue in how far the interpretation of the ASTEC
trial may be blurred by the fact that a relevant part of
the patients received radiotherapy (~ 25%) may be
answered by taking the results of the PORTEC-2 trial
into account: The PORTEC-2 study collective was simi-
lar to the cohort treated inside the ASTEC trial with
one major difference: Lymph-node sampling was not
performed at all - nevertheless outcomes in term of
local control DFS and OS were similar. Thus, the results
from PORTEC-2 strongly support the interpretation
from the ASTEC lymph-node dissection trial.
A frequently discussed limitation of both trials is the
fact that a systematic removal of the para-aortal nodes
has not been performed. Since the initial analysis by
Creasman and Alders [1,31] it is known that, in parallel
to the increasing risk for pelvic lymph node metastasis,
the proportion of positive para-aortic lymph node
increases. A recent retrospective Japanese trial analysed
outcomes (overall survival) in 671 patients with endo-
metrial carcinoma treated with either pelvic lymphade-
nectomy (n = 325 patients) or pelvic and para-aortic
lymphadenectomy (n = 346). Additional adjuvant treat-
ments were offered to patients with intermediate or
high risk of recurrence [32].
Overall survival was better in those patients with pel-
vic and para-aortic lymphadenectomy when compared
to pelvic lymphadenectomy alone (HR 0.53, 95% CI
0.38-0.76; p = 0.0005). No difference was detectable
between intermediate or high-risk patients whereas
overall survival was not influenced by lymphadenectomy
type in low-risk patients. In multivariate analysis pelvic
and para-aortic lymphadenectomy reduced the risk of
death compared with pelvic lymphadenectomy in inter-
mediate to high-risk patients (HR 0.44, 0.30-0.64; p <
0.0001).
Conclusion and future developments
Although the recent data add substantial new aspects for
guiding the treatment of patients with endometrial can-
cer, many aspects are still ill-defined. The randomized
data on either radiotherapy or systematic lymphadenect-
omy indicate that the general impact of a more aggressive
approach on overall survival in most patients is rather
limited. However, there are enough hints pointing to the
interpretation that in certain subgroups a more aggres-
sive approach is advisable. Unfortunately - at present -
these groups are not defined. It is likely that patients with
high-risk cancer need an optimal local treatment in par-
allel to effective systemic treatment. The outcome of
patients suffering from pT1c G3 treated within the obser-
vational arm of the PORTEC-1 trial indicates that surgery
and radiation finally lead to high local control rates how-
ever many of those patient fail distantly. Vice versa, strat-
egy with surgery plus chemotherapy may be associated
with unacceptably high local failure rates [33].
Merely for all low-risk patients the data point to a more
minimalistic approach. Taken into account that all POR-
TEC data were based on a simple TAH-BSO without any
lymphadenectomy and none of the prospective trials
documented any benefit of extended surgery, surgery
may be limited to a TAH-BSO. Adjuvant radiotherapy
may also be limited to vaginal vault irradiation.
Still all prospective trials are subject to certain criti-
cisms: It is frequently stated that the validity of the Italian
trial as well as the ASTEC trial is limited by the fact that
irradiation was used in a substantial number of the Italian
patients and the absolute number of nodes removed was
not perfectly high. However, at least for the cohort
included in the trial the results of the PORTEC-2 trial
make systematic removal of nodes questionable. In addi-
tion the general value of the PORTEC-2 is partially ques-
tioned based on the high proportion of patients with
grade 1 cancer.
The value of either the ASTEC EN.5 trial, the Italian
trial and also the Japanese cohort study is limited by
complex biases introduced by the uncontrolled use of
additional adjuvant treatment or crossovers.
Thus at present the treating clinician should be aware
of the data suggesting a reduced aggressiveness for low-
risk patients. In parallel the crucial recommendation
issued by P. Eifel in her recent position paper should be
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followed strictly: “The PORTEC-2 trial underscores the
critical role of pathologists and other specialists in the
management of uterine carcinomas. These cancers are
best managed in an environment where there is an
experienced multidisciplinary team of gynaecologic
oncologists, radiation oncologists, and gynaecologic
pathologists. Management by less experienced clinicians
can result not only in confusing trial results but also in
inappropriate therapies, treatment delays, and added
costs to society”.
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